biostudies-literatureUnknown13Pan L<b>Background:</b> In China, <i>Coptis chinensis</i> Franch. (Chinese name: Huanglian) prescriptions (HLPs) are prominent hypoglycemic agents used in glycemic control. However, the curative effect of HLPs as adjunctive therapies for type 2 diabetes mellitus (T2DM) has not been evaluated. Based on a systematic review and a meta-analysis, this study was conducted to assess the effects of HLPs combined with metformin as a reinforcing agent for T2DM. <b>Materials and methods:</b> A total of 33 randomized controlled trials (RCTs) reporting on 2,846 cases concerning the use of HLPs in the treatment of T2DM were identified from the China National Knowledge Infrastructure (CNKI), Weipu (VIP), Wanfang, PubMed, Cochrane Library, and EMBASE databases. Primary outcomes included fasting blood glucose (Frontiers in pharmacology956313https://www.ebi.ac.uk/biostudies/studies/S-EPMC9492976biostudies-literatureSystematic review and meta-analysis of <i>Coptis chinensis</i> Franch.-containing traditional Chinese medicine as an adjunct therapy to metformin in the treatment of type 2 diabetes mellitus.PMC9492976Duan ZXu KZhai XPan LLiu GfalseSystematic review and meta-analysis of <i>Coptis chinensis</i> Franch.-containing traditional Chinese medicine as an adjunct therapy to metformin in the treatment of type 2 diabetes mellitus.<b>Background:</b> In China, <i>Coptis chinensis</i> Franch. (Chinese name: Huanglian) prescriptions (HLPs) are prominent hypoglycemic agents used in glycemic control. However, the curative effect of HLPs as adjunctive therapies for type 2 diabetes mellitus (T2DM) has not been evaluated. Based on a systematic review and a meta-analysis, this study was conducted to assess the effects of HLPs combined with metformin as a reinforcing agent for T2DM. <b>Materials and methods:</b> A total of 33 randomized controlled trials (RCTs) reporting on 2,846 cases concerning the use of HLPs in the treatment of T2DM were identified from the China National Knowledge Infrastructure (CNKI), Weipu (VIP), Wanfang, PubMed, Cochrane Library, and EMBASE databases. Primary outcomes included fasting blood glucose (2022-01-01T00:00:00Z20222025-04-21T20:17:33.454Z2024-12-04T01:10:43.37ZS-EPMC94929763616040510.3389/fphar.2022.956313